title: Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay.
abstract: Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels underlie the pacemaker currents in neurons (I(h)) and cardiac (I(f)) cells. As such, the identification and characterization of novel blockers of HCN channels is important to enable the dissection of their function in vivo. Using a new IonWorks HT electrophysiology assay with human HCN1 and HCN4 expressed stably in cell lines, four HCN channel blockers are characterized. Two blockers known for their activity at opioid/Ca(2+) channels and K(+) channels, loperamide and CP-339,818 (respectively), are described to block HCN1 more potently than HCN4. The known HCN blocker ZD7288 was also found to be more selective for HCN1 over HCN4, while the HCN blocker DK-AH269 was equipotent on HCN4 and HCN1. Partial replacement of the intracellular Cl(-) with gluconate reduced the potency on both channels, but to varying degrees. For both HCN1 and HCN4, ZD7288 was most sensitive in lower Cl(-) solutions, while the potency of loperamide was not affected by the differing solutions. The block of HCN1 for all compounds was voltage-dependent, being relieved at more negative potentials. The voltage-dependent, Cl(-) dependent, HCN1 preferring compounds described here elaborate on the current known pharmacology of HCN channels and may help provide novel tools and chemical starting points for the investigation of HCN channel function in natively expressing systems.
authors.affiliation: Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, United States.
authors.forename: Yan T
authors.initials: YT
authors.lastname: Lee
authors.forename: Dmitry V
authors.initials: DV
authors.lastname: Vasilyev
authors.forename: Qin J
authors.initials: QJ
authors.lastname: Shan
authors.forename: John
authors.initials: J
authors.lastname: Dunlop
authors.forename: Scott
authors.initials: S
authors.lastname: Mayer
authors.forename: Mark R
authors.initials: MR
authors.lastname: Bowlby
mesh_terms: D000634:Aminoquinolines; D000930:Antidiarrheals / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism; D054815:Cyclic Nucleotide-Gated Cation Channels / Q000037:antagonists & inhibitors* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D064428:Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; D007097:Imines; D008139:Loperamide / Q000494:pharmacology*; D009124:Muscle Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D015221:Potassium Channels / Q000502:physiology; D011743:Pyrimidines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*
chemical_list: D000634:Aminoquinolines; D000930:Antidiarrheals; D001552:Benzazepines; C529069:CP-339,818; D002712:Chlorides; D054815:Cyclic Nucleotide-Gated Cation Channels; C578665:HCN1 protein, human; C119587:HCN4 protein, human; D064428:Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; D007097:Imines; D009124:Muscle Proteins; D015221:Potassium Channels; D011743:Pyrimidines; D011804:Quinolines; C082246:ICI D2788; C087873:DK-AH 268; D008139:Loperamide